Bortezomib-Induced Tumor Lysis Syndrome in a Patient With HIV-Negative Plasmablastic Lymphoma

The biology and treatment of plasmablastic lymphoma

“…55 Bortezomib alone and in combination with chemotherapy has been used with limited efficacy in HIV-positive and HIV-negative patients with relapsed PBL. [56][57][58][59][60][61][62] More recently, a case series of 3 previously untreated patients with PBL, 2 of them HIV-positive, has shown efficacy with the combination of bortezomib and dose-adjusted EPOCH. 63 The immunomodulator lenalidomide induced a temporary response in a patient with relapsed PBL.…”

Plasmablastic Lymphoma of the Maxillary Sinus: Case Report of a Novel Treatment Approach of Concurrent Bortezomib and Intensity-Modulated Radiotherapy

“…He was treated appropriately, and 2 weeks later, he had full resolution of all palpable sites of disease. He later succumbed to sepsis secondary to a urinary tract infection about 30 days after his first cycle [7].…”

“…Three recent case reports have reported the potential benefit of the proteasome inhibitor, bortezomib, in the treatment of PBL [7][8][9]. Bortezomib acts by blocking NF-kB and sensitizing PBL to cytotoxic chemotherapy ultimately inducing cell cycle arrest and apoptosis.…”

Onco-Nephrology

“…TLS most commonly follows treatment of hematologic malignancies, such as acute lymphocytic or lymphoblastic leukemia, acute myeloid leukemia, and Burkitt lymphoma, but also occurs after treatment of other bulky or rapidly growing tumors, particularly if highly sensitive to the effects of cytotoxic chemotherapy (2)(3)(4). TLS has been reported after treatment with conventional chemotherapy, dexamethasone (5), and newer agents such as bortezomib (6,7), thalidomide (8,9), and rituximab (10); radiation therapy of radio-sensitive solid tumors (11); and total-body irradiation (12).…”